Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CEMPRA, INC. (MLNT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update ~ Revenue of $14.1 million, Including Net Product Sales of $11.8 million, for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million, Year-Over-Year~ ~ Filed Supplemental New Drug Application for Baxdela ® for the Treatment of Community-Acquired Bacterial Pneumonia~"
03/13/2019 8-K Quarterly results
Docs: "Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results ~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018, up 32 Percent from Prior Quarter ~ ~ Corporate Milestones Across Commercial Operations, Clinical and Business Development Provide Critical Growth Opportunities ~ ~ Provides Guidance for 2019 ~",
"Investor Presentation"
11/07/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Commitment Letter, by and between Melinta Therapeutics, Inc. and Vatera Healthcare Partners LLC",
"Melinta Therapeutics Reports Third Quarter 2018 Financial Results",
"Investor Presentation"
08/07/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Melinta Therapeutics Reports Second Quarter 2018 Financial Results",
"Investor presentation"
03/13/2018 8-K Quarterly results
Docs: "Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results",
"Investor presentation"
08/09/2017 8-K Quarterly results
Docs: "CEMPRA PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS"
04/28/2017 8-K Quarterly results
Docs: "CEMPRA REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
10/27/2016 8-K Quarterly results
Docs: "Cempra Reports Third Quarter 2016 Financial Results and Provides Corporate Update"
08/01/2016 8-K Form 8-K - Current report
05/02/2016 8-K Form 8-K - Current report
02/24/2016 8-K Quarterly results
Docs: "Cempra Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update"
10/22/2015 8-K Quarterly results
Docs: "Cempra Reports Third Quarter 2015 Financial Results and Provides Corporate Update"
07/29/2015 8-K Quarterly results
Docs: "Cempra Reports Second Quarter 2015 Financial Results and Provides Corporate Update"
04/30/2015 8-K Quarterly results
Docs: "Cempra Reports First Quarter 2015 Financial Results and Provides Corporate Update"
02/25/2015 8-K Quarterly results
Docs: "Cempra Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update"
10/29/2014 8-K Quarterly results
Docs: "Cempra Reports Third Quarter 2014 Financial Results and Provides Corporate Update"
07/29/2014 8-K Quarterly results
Docs: "Cempra, Inc. Reports Second Quarter 2014 Financial and Operating Results - Company to Host Conference Call and Webcast at 4:30 p.m. EDT, Today, July 29, 2014 - CHAPEL HILL, N.C. - July 29, 2014 - Cempra, Inc. , a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the second quarter and six months ended June 30, 2014. The company will host a conference call and webcast at 4:30 p.m. EDT, today. “We expect that SOLITAIRE-Oral will complete enrollment according to plan and top-line data will be available no later than the first quarter of 2015,” said Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra. “Regarding SOLITAIRE-IV, sites are being i..."
04/29/2014 8-K Quarterly results
Docs: "Cempra, Inc. Reports First Quarter 2014 Financial and Operating Results - Company to Host Conference Call and Webcast at 4:30 p.m. EDT, Today, April 29, 2014 - CHAPEL HILL, N.C. - April 29, 2014 - Cempra, Inc. , a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2014. The company will host a conference call and webcast at 4:30 p.m. EDT, today. “In the first quarter of 2014, we continued patient enrollment of our two Phase 3 clinical trials of oral solithromycin, SOLITAIRE Oral, and IV-to-oral solithromycin, SOLITAIRE-IV, in patients with community-acquired bacterial pneumonia or CABP,” said Prabhavathi Fernandes, Ph...."
02/27/2014 8-K Quarterly results
Docs: "Cempra, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating Results - Company to Host Conference Call and Webcast at 4:30 p.m. EST, Today, Feb. 27, 2014 - CHAPEL HILL, N.C. - Feb. 27, 2014 - Cempra, Inc. , a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the fourth quarter and full year ended Dec. 31, 2013. The company will host a conference call and webcast at 4:30 p.m. EST, today. “2013 has been a year of significant achievement for Cempra through the advancement of our Phase 3 and Phase 2 clinical programs and the strengthening of our financial position,” said Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra. “S..."
10/29/2013 8-K Form 8-K - Current report
07/30/2013 8-K Form 8-K - Current report
04/25/2013 8-K Form 8-K - Current report
02/28/2013 8-K Quarterly results
Docs: "Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results - Company to Host Conference Call and Webcast at 4:30 p.m. EST, Today, Feb. 28, 2013 -"
11/08/2012 8-K Form 8-K - Current report
08/08/2012 8-K Form 8-K - Current report
05/10/2012 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy